Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
- 20 June 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (18), 2983-2990
- https://doi.org/10.1200/jco.2008.20.2630
Abstract
Purpose: To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL. Patients and Methods: Eligible patients had relapsed/refractory HCL and needed treatment based on blood counts. Patients were stratified into three groups: response to cladribine less than 1 year, those with a response lasting 1 to 4 years, or no response and uncontrolled infection. Patients received BL22 40 μg/kg every other day for three doses on cycle 1. Those achieving hematologic remission (HR), defined as neutrophils ≥ 1,500/mm3, hemoglobin ≥ 11 g/dL, and platelets ≥ 100,000/mm3, were observed. Patients without HR were re-treated at 30 μg/kg every other day for three doses every 4 weeks beginning at least 8 weeks after cycle 1. Results: Thirty-six patients were enrolled including 26, nine, and one in groups 1 to 3. The response after one cycle (CR, 25%; PR, 25%) improved when 56% were re-treated (CR, 47%; PR, 25%). CR rate was similar in groups 1 and 2 (P = .7). Twenty-two with baseline spleen height lower than 200 mm had higher CR (64% v 21%; P = .019) and OR rates (95% v 36%; P = .0002) compared to 14 with spleens either absent or higher than 200 mm. The only serious toxicity was reversible grade 3 hemolytic uremic syndrome, not requiring plasmapheresis, in two patients (6%). High neutralizing antibodies were observed in four patients (11%) and prevented re-treatment. Conclusion: BL22 activity in HCL is confirmed. Best responses to BL22 after cladribine failure are achieved before the patients develop massive splenomegaly or undergo splenectomy.Keywords
This publication has 28 references indexed in Scilit:
- A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicityBlood, 2009
- An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopesProceedings of the National Academy of Sciences of the United States of America, 2008
- Immunotoxin Treatment of CancerAnnual Review of Medicine, 2007
- Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell MalignanciesJournal of Clinical Oncology, 2005
- Rituximab in relapsed or refractory hairy cell leukemiaBlood, 2003
- Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemiaBlood, 2003
- Thrombotic MicroangiopathiesThe New England Journal of Medicine, 2002
- Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell LeukemiaThe New England Journal of Medicine, 2001
- The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodiesCellular Immunology, 1989
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974